Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
3.
Can Fam Physician ; 62(5): 393-5, 2016 05.
Article in French | MEDLINE | ID: mdl-27255619
4.
Pediatr Infect Dis J ; 28(8): 697-701, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19461554

ABSTRACT

OBJECTIVES: To examine risk factors for lower respiratory tract infections (LRTI) hospital admission in the Canadian Arctic. METHODS: This was a case-control study during a 14-month period among children less than 2 years of age. Cases were admitted to the Baffin Regional Hospital in Iqaluit, Nunavut with LRTI. Controls were age matched and came from Iqaluit and 2 communities. Odds ratios (ORs) of hospital admission for LRTI were estimated through multivariate conditional logistic regression modeling for following risk factors: smoking in pregnancy, Inuit race, prematurity, adoption status, breast-feeding, overcrowding, and residing outside of Iqaluit. Viruses in nasophayngeal aspirates were sought at the time of each hospital admission. RESULTS: There were 101 age-matched cases and controls. The following risk factors were significantly associated with an increased risk of admission for LRTI (adjusted OR): smoking in pregnancy (OR = 4.0; 95% CI: 1.1-14.6), residence outside of Iqaluit (OR = 2.7; 95% CI: 1.0 -7.2), full Inuit race (OR = 3.8; 95% CI: 1.1-12.8), and overcrowding (OR = 2.5, 95% CI: 1.1- 6.1). Non-breast-fed children had a 3.6-fold risk of being admitted for LRTI (95% CI: 1.2-11.5) and non-breast-fed adopted children had a 4.4-fold increased risk (95% CI: 1.1-17.6) when compared with breast-fed, nonadopted children. Prematurity was not associated with an increased risk of admission. Viruses were identified in 88 (72.7%) of admissions, with respiratory syncytial virus being identified in the majority of admissions, 62 (51.2%). Multiple viruses were isolated in 19 (15.7%) admissions. CONCLUSIONS: Smoking during pregnancy, place of residence, Inuit race, lack of breast-feeding, and overcrowding were all independently associated with increased risk of hospital admission for LRTI among Inuit children less than 2 years of age. Future research on the role of adoption and genetics on the health of Inuit children are required.


Subject(s)
Inuit , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Virus Diseases/epidemiology , Virus Diseases/virology , Breast Feeding , Canada/epidemiology , Case-Control Studies , Chi-Square Distribution , Hospitalization , Humans , Infant , Logistic Models , Orthomyxoviridae/isolation & purification , Respiratory Syncytial Viruses/isolation & purification , Respiratory Tract Infections/ethnology , Rhinovirus/isolation & purification , Risk Factors , Smoking , Statistics, Nonparametric , Virus Diseases/ethnology
5.
Pediatr Infect Dis J ; 28(8): 702-6, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19461555

ABSTRACT

BACKGROUND: The objectives were to compare actual respiratory syncytial virus (RSV) hospitalization rates and costs in a cohort of Inuit infants to hypothetical palivizumab prophylaxis strategies for infants of all gestational ages in the Eastern Canadian Arctic. METHODS: Incidence and costs of RSV hospitalization were collected for infants admitted to the Baffin Regional Hospital in 2002, before the initiation of palivizumab. There was a comparison of the actual costs to the costs associated with 8 palivizumab strategies stratified by age (<6 months, <1 year) and location (overall, town [Iqaluit], rural communities). It was assumed that each category would receive universal palivizumab prophylaxis resulting in a 78% decrease in RSV admissions. The net costs incurred, number needed to treat (NNT), and incremental costs per hospitalization avoided were calculated for each comparison. RESULTS: There was a great variation in the rates and costs associated with RSV admissions between Iqaluit and the communities. For infants <1 year of age residing in Iqaluit, the mean admission cost was $3915, and palivizumab prophylaxis had an NNT of 20.4 and cost of $162,551 per admission avoided. For rural infants <6 months, the mean cost of admission was $23,030, and palivizumab prophylaxis resulted in an NNT of 3.9 to 2.5 and cost savings of up to $8118 per admission avoided. CONCLUSIONS: Due to the high rates and costs associated with RSV admissions, administration of palivizumab in rural communities in the Canadian Arctic to infants less than 6 months of age could result in net cost savings.


Subject(s)
Antibiotic Prophylaxis/economics , Antibodies, Monoclonal/therapeutic use , Hospitalization/economics , Inuit , Respiratory Syncytial Virus Infections/economics , Respiratory Syncytial Viruses/isolation & purification , Respiratory Tract Infections/economics , Antibodies, Monoclonal/economics , Antibodies, Monoclonal, Humanized , Antiviral Agents/economics , Antiviral Agents/therapeutic use , Canada , Humans , Infant , Palivizumab , Respiratory Syncytial Virus Infections/drug therapy , Respiratory Syncytial Virus Infections/ethnology , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/prevention & control , Respiratory Tract Infections/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...